The promise of biomarkers for personalized renal cancer care.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 20393489.
- Also identified by DOI 10.1038/ki.2010.26.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Biomarkers hold promise for personalizing renal cancer care by potentially identifying patients most likely to benefit from novel therapies. Porta and colleagues report that among subjects with advanced renal-cell carcinoma receiving sunitinib treatment, those with above-normal levels of the circulating biomarkers vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin displayed significantly lower progression-free survival times. This Commentary reviews the current status of these biomarkers with respect to methodological issues, specificity, and biological plausibility.
Medical subject headings
- Biomarkers
- Carcinoma, Renal Cell
- Kidney Neoplasms
- Neoplasms